42 results about "Interferon tau" patented technology

The present invention is directed to the field of animal and human health, and more particularly to pharmacological uses of analogs or mutants of interferon-tau (IFN-tau) that differ from native IFN-tau because of substitutions of amino acids near the amino terminus of the IFN-tau molecule that impart improved biological activity. The IFN-tau mutants described in this disclosure have low toxicity, retain the same or slightly reduced antiviral activity compared with highly effective IFN-alpha, and have enhanced antiproliferative activity compared to native IFN-tau, making them useful in treating viral infections, cancer, and immune system diseases including autoimmune diseases. The present invention is also directed to a method for making novel recombinant proteins, especially interferons, interleukins, and cytokines, polypeptide hormones and other biopharmaceuticals that have improved biological activity over known proteins and / or lower toxicity and / or increased stability.

Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.

The present invention includes interferon-tau (IFNτ) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.

A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2′,5′-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-τ, in a dosage effective to stimulate bloodstream levels of 2′,5′-oligoadenylate synthetase.

A method of treating conditions responsive to therapy with interferon-alpha or interferon-beta is provided, where the dose of interferon-alpha or interferon-beta is reduced and a dose of interferon-tau is additionally administered. The method results in efficacious therapy with a reduction in unwanted adverse events.

The present invention includes interferon-tau (IFNτ) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.

Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antiviral and / or antitumor agents. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFNτ) protein. Methods of combination therapy are also described.

Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFNτ) protein. Methods of treating viral diseases and other disorders with the polymer-modified IFNα analog protein are also described.

The invention discloses a fusion protein composed of sheep albumin, interferon Tau and interleukin 2, a preparation method thereof and its coding gene, and sheep long-acting interferon. The fusion protein is linked by sheep albumin, sheep interferon Tau and sheep interleukin 2 through a flexible linker, the fusion protein of sheep albumin, interferon Tau and interleukin 2 is obtained, its coding gene is designed and optimized, and recombinant sheep long-acting interferon is finally prepared. The recombinant sheep long-acting interferon can obviously increase half life of sheep interferon, thehalf life is increased by more than 17 times by comparing with that of common sheep interferon, and the recombinant sheep long-acting interferon has wide spectrum antiviral effect and increases the sheep self immune response.

A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2′,5′-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-τ, in a dosage effective to stimulate bloodstream levels of 2′,5′-oligoadenylate synthetase.

The invention discloses a fusion protein consisting of sheep interleukin 2, sheep interferon gamma and sheep interferon tau and a preparation method thereof. The fusion protein is formed by connectingthe sheep interleukin 2, sheep interferon gamma and sheep interferon tau through a flexible linker, and a recombinant sheep long-acting interferon can be obtained through freeze drying after the fusion protein is compounded with a freeze-drying protective additive. The recombinant sheep long-acting interferon can obviously improve the half-life period of the sheep interferon, the half-life periodof the sheep interferon is prolonged by more than 17 times by compared with that of common sheep interferon, the fusion protein has a broad-spectrum antiviral role, and the immune response of sheep can be improved.

The invention discloses a sheep interferon Tau biological activity detection method and application thereof. The method includes following steps: adopting PCR amplification to acquire a gene segment of Mxp of sheep Mx protein; removing pCMV of pEGFP-N1 carrier plasmid; using the gene segment of Mxp of the sheep Mx protein obtained through PCR amplification to replace pCMV in original pEGFP-N1 carrier plasmid through T4DNA ligase to build pEGFP-N1-Mxp plasmid; using the pEGFP-N1-Mxp plasmid to transfect cells, and screening out a stable transfection cell line through neomycin; performing cloning culture on the screened stable transfection cell line, and adding sheep interferon Tau to co-incubate with the stable transfection cell line after going through cloning culture. In this way, Mx genepromoter activity can be activated to promote expression of EGFP in cells, and intensity of fluorescence emitted by the cells after being irradiated by an excitation light source is in positive correlation with biological activity of the sheep interferon Tau, so that the biological activity of the sheep interferon Tau can be evaluated quantitatively.

Methods of treating an autoimmune condition by administering IFNtau are described. IFNtau is administered orally at a dose sufficient to obtain a desired clinical endpoint, such as a reduction in new contrast-enhanced brain lesions in multiple sclerosis patients.